Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Fatty liver; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms E-LIFT
- 20 Mar 2018 Primary endpoint (Change in Liver Fat) has been met, according to results presented at The 100th Annual Meeting of the Endocrine Society.
- 20 Mar 2018 Results (n=50) assessing effect of empagliflozin on liver fat in patients with type 2 diabetes and NAFLD, were presented at The 100th Annual Meeting of the Endocrine Society.
- 13 Mar 2018 Status changed from active, no longer recruiting to completed.